3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with Degenerative Diseases, Central Nervous System in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asenbaum, S; Kovacs, GG; Perju-Dumbrava, L; Pirker, S; Pirker, W; Traub-Weidinger, T | 1 |
| Hahn, K; Linke, R; Pöpperl, G; Radau, P; Tatsch, K | 1 |
1 trial(s) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Diagnostic performance of a 3-D automated quantification method of dopamine D2 receptor SPECT studies in the differential diagnosis of parkinsonism.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Benzamides; Corpus Striatum; Diagnosis, Differential; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Imaging, Three-Dimensional; Male; Middle Aged; Neurodegenerative Diseases; Parkinson Disease; Pyrrolidines; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Dopamine D2; Reproducibility of Results; Sensitivity and Specificity | 2005 |
1 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Degenerative Diseases, Central Nervous System
| Article | Year |
|---|---|
Dopamine D2 receptor SPECT in corticobasal syndrome and autopsy-confirmed corticobasal degeneration.
Topics: Aged; Autopsy; Basal Ganglia Diseases; Benzamides; Dopamine Antagonists; Female; Humans; Male; Middle Aged; Neurodegenerative Diseases; Pyrrolidines; Radiopharmaceuticals; Receptors, Dopamine D2; Retrospective Studies; Syndrome; Tomography, Emission-Computed, Single-Photon | 2013 |